3-(2-methoxyethyl) 5-(3-phenylprop-2-en-1-yl) 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate

• ChemBase编号: 72614
• 分子式: C27H28N2O7
• 平均质量: 492.52042
• 单一同位素质量: 492.18965125
• SMILES: c1ccc(cc1C1C(=C(NC(=C1C(=O)OCCOC)C)C)C(=O)OC/C=C/c1ccccc1)[N+](=O)[O-]
• Canonical SMILES: COCCOC(=O)C1=C(C)NC(=C(C1c1cccc(c1)[N+](=O)[O-])C(=O)OC/C=C/c1ccccc1)C
• InChI: InChI=1S/C27H28N2O7/c1-18-23(26(30)35-14-8-11-20-9-5-4-6-10-20)25(21-12-7-13-22(17-21)29(32)33)24(19(2)28-18)27(31)36-16-15-34-3/h4-13,17,25,28H,14-16H2,1-3H3/b11-8+
• InChIKey: KJEBULYHNRNJTE-DHZHZOJOSA-N

名称和登记号

名称

• IUPAC标准名: 3-(2-methoxyethyl) 5-(3-phenylprop-2-en-1-yl) 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; 3-(2-methoxyethyl) 5-(2E)-3-phenylprop-2-en-1-yl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
• IUPAC传统名: 3-(2-methoxyethyl) 5-(3-phenylprop-2-en-1-yl) 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; cilnidipine; 3-(2-methoxyethyl) 5-(2E)-3-phenylprop-2-en-1-yl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; atelec
• 别名: 1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 2-methoxyethyl (2E)-3-phenyl-2-propenyl ester; Cilnidipine; FRC 8653; Cilnidipine; Atelec; 1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic Acid 2-Methoxyethyl (2E)-3-Phenyl-2-propenyl Ester, FRC-8653, Atelec, Cinalong, Siscard,; 3-CinnaMyl 5-(2-Methoxyethyl) 2,6-diMethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate

登记号

• CAS号: 132203-70-4
• MDL号: MFCD00865853
• PubChem SID: 162037539; 24892414
• PubChem CID: 5282138

理论计算性质

• 质子受体: 6
• 质子供体: 1
• LogD (pH = 5.5): 4.1029077
• LogD (pH = 7.4): 4.1029077
• Log P: 4.1029077
• 摩尔折射率: 137.1352 cm^3
• 极化性: 51.402103 Å^3
• 极化表面积: 117.0 Å^2
• 可自由旋转的化学键: 12
• 里宾斯基五规则: true
• Acid pKa: 19.46359

分子性质

理化性质

• 溶解度: Chloroform; DMSO: ≥20 mg/mL; H2O: ≤2 mg/mL
• 外观: light yellow powder; Pale Yellow Solid
• 熔点: 97-99°C

安全信息

• 保存条件: -20°C; -20°C Freezer; protect from light
• RTECS编号: US7975550
• 欧盟危险性物质标志: 刺激性(Irritant) (Xi)
• 德国WGK号: 3
• 危险公开号: 41
• 安全公开号: 26-39
• GHS危险品标识: GHS05
• GHS警示词: Danger
• GHS危险声明: H318
• GHS警示性声明: P280-P305 + P351 + P338
• 个人保护装置: dust mask type N95 (US), Eyeshields, Gloves

药理学性质

• 作用靶点: calcium channe
• 生物活性机理: Calcium channel blocker

产品相关信息

• 纯度: ≥98% (HPLC); 97%
• 成盐信息: Free Base
• 应用领域: Antihypertensive agent; Cardiovascular agent
• Empirical Formula (Hill Notation): C27H28N2O7

详细说明

Selleck Chemicals - S1293

Research Area: Neurological Disease
Biological Activity:
Cilnidipine is a calcium channel blocker. It is a dual blocker of L-type voltage-gated calcium channels in vascular smooth muscle and N-type calcium channels in sympathetic nerve terminals that supply blood vessels. [1]References on Cilnidipine[1] http://en.wikipedia.org/wiki/Cilnidipine, ,

Sigma Aldrich - C1493

包装
Protect from high temperatures.
Biochem/physiol Actions
Cilnidipine is a slow-acting Ca2+ channel blocker; antihypertensive; vasodilator; dual blocker of L-type voltage-gated Ca2+ channels in vascular smooth muscle and N-type Ca2+ channels in sympathetic nerve terminals that supply blood vessels. Cilnidipine may offer an advantage over nifedipine as the long term intake of the latter has been linked to increased risk of myocardial infarction and mortality in patients with coronary artery disease. Cilnidipine lowers blood pressure, but has less effect on sympathetic activity. Unlike nifedipine, cilnidipine does not inhibit PKC.

Toronto Research Chemicals - C441375

A dihydropyridine calcium channel blocker.

参考文献

• http://en.wikipedia.org/wiki/Cilnidipine
• Ikeda, K., et al.: Oyo Yakuri, 44, 433 (1992)
• Hosono, M., et al.: J. Pharmacobio-Dyn., 15, 547, (1992)
• Ishii, M.: Japan Pharmacol. Ther., 21, 59 (1992)
• Japan. Pat., 1988, Fujirebio, 63 208 573; CA, 110, 95014j, (synth, pharmacol)
• Oike, M. et al., Circ. Res., 1990, 67, 993, (pharmacol)
• Nakashima, M. et al., Jpn. J. Pharmacol., 1991, 57, 51, (pharmacol)
• Hatada, K. et al., J. Chromatogr., 1992, 583, 116, (hplc-ms)
• Yoshimoto, R. et al., J. Pharmacobio-Dyn., 1992, 15, 25, (pharmacol)
• Uneyama, H. et al., Cardiovasc. Drug Rev., 1999, 17, 341-357, (rev)
• Martindale, The Extra Pharmacopoeia, 32nd edn., Pharmaceutical Press, 1999, 841